Ophthalmic herpes zoster

Summary

Ophthalmic herpes zoster (MONDO:0005883) is a disease and 1 clinical trial. Top therapeutic interventions include valacyclovir. A subtype of trigeminal nerve disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ophthalmic herpes zoster
Mondo ID	MONDO:0005883
EFO	EFO:0007403
MeSH	D006563
SNOMED CT	87513003
UMLS	C0019364
MedGen	9236
GARD	0009721
Anatomy (UBERON)	UBERON:0000348
Is cancer (heuristic)	no

Also known as: herpes zoster ophthalmicus · Herpes zoster ophthalmicus (HZO) · HZO

Disease family

This is a subtype of trigeminal nerve disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › cranial nerve neuropathy › trigeminal nerve disorder › ophthalmic herpes zoster

Related subtypes (3): trigeminal nerve neoplasm, trigeminal neuralgia, trigeminal autonomic cephalalgia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

4 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Cortisone Acetate	Approved (phase 4)
Dexamethasone	Approved (phase 4)
Prednisolone	Approved (phase 4)
Prednisone	Approved (phase 4)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Hypromellose.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03134196	PHASE4	COMPLETED	Zoster Eye Disease Study

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
VALACYCLOVIR	4	1